FDA Approves T-DXd for 2 New Indications in Early-Stage HER2-Positive Breast CancerByJason M. BroderickMay 16th 2026
UGN-103 Shows Durable Disease Control in LG-IR-NMIBC, Paving Path for FDA SubmissionByJason M. BroderickMay 15th 2026
VIKTORIA-2 Trial Evolves to Evaluate Gedatolisib in Endocrine-Sensitive and -Resistant Breast CancerBySabrina SeraniMay 15th 2026
FDA Grants Fast Track Designation to Suplexa for MSI-H Colorectal CancerByJason M. BroderickMay 15th 2026